MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/hep.0000000000001764

Медицинская библиотека · Hepatology (Baltimore, Md.) · 2026

Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with early hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial).

Nahon Pierre, Ziol Marianne, Pan Long, Portal Jean-Jacques, Oberti Frederic, Aube Christophe, Blanc Jean-Frederic, Trillaud Hervé, Merle Philippe, Rode Agnès, Assenat Eric, Guiu Boris, Lequoy Marie, Cornelis François, Bouattour Mohamed, Talib Zohra, Tibi Annick, Zeng Qinghe, Bouda Yasmine, Ganne-Carrié Nathalie, Sutter Olivier, Sutton Angela, Guyot Erwan, Barget Nathalie, Zucman-Rossi Jessica, Campani Claudia, Bamba-Funck Jessica, Calderaro Julien, Nault Jean-Charles, Vicaut Eric, Seror Olivier

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIMS: Irreversible electroporation (IRE) is a non-thermal ablation technique suited for difficult-to-treat hepatocellular carcinoma (HCC) with 1-year local recurrence (LR) rates above 50%. We hypothesized that peri-procedural immunotherapy could synergize with IRE to decrease local recurrence.

APPROACH AND

RESULTS

NIVOLEP is a multicenter phase 2 trial evaluating nivolumab combined with IRE in patients with BCLC A HCC. Patients received 2 neoadjuvant nivolumab infusions, IRE with curative intent, and 12 monthly adjuvant nivolumab infusions. Tumor biopsies were performed at baseline and during IRE. The primary endpoint was 1-year local recurrence-free survival (LRFS). In all, 62 HCC nodules (mean size: 30.0 mm) from 43 patients (mean age: 71 y, 88% male, 81% cirrhosis) were considered. All patients received neoadjuvant nivolumab; 35 underwent curative IRE (8 others: 4 IRE failures, 3 HCC progressions, 1 death). After neoadjuvant nivolumab, radiological or pathological response was observed in 24.2% and 26.3% nodules, respectively. One-year LRFS was 70.6% (95% CI: 55.3-85.9), and 2-year overall survival was 74.2% in the intention-to-treat analysis. Grade 3 or 4 adverse events related to nivolumab occurred in 2 patients; 1 patient died due to nivolumab. RNA-sequencing analysis of the tumor after neoadjuvant nivolumab showed an enrichment of pathways associated with leukocyte migration, T cell activation, and CD8+ T and B-cell infiltration associated with pathological response. Circulating protein variations were associated with pathological or radiological responses and local recurrence.

CONCLUSIONS

Neoadjuvant and adjuvant nivolumab in BCLC A HCC patients eligible for IRE lead to pathological response related to immune activation and show anti-tumoral effect.

Для цитирования: Nahon Pierre, Ziol Marianne, Pan Long, Portal Jean-Jacques, Oberti Frederic, Aube Christophe, Blanc Jean-Frederic, Trillaud Hervé, Merle Philippe, Rode Agnès, Assenat Eric, Guiu Boris, Lequoy Marie, Cornelis François, Bouattour Mohamed, Talib Zohra, Tibi Annick, Zeng Qinghe, Bouda Yasmine, Ganne-Carrié Nathalie, Sutter Olivier, Sutton Angela, Guyot Erwan, Barget Nathalie, Zucman-Rossi Jessica, Campani Claudia, Bamba-Funck Jessica, Calderaro Julien, Nault Jean-Charles, Vicaut Eric, Seror Olivier. Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with early hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial).. Hepatology (Baltimore, Md.). 2026. DOI: 10.1097/hep.0000000000001764.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.